Basic Information
Pregabalin Pfizer
Regulatory Information
EMEA/H/C/003880
April 10, 2014
February 20, 2014
35
August 30, 2024
Company Information
Netherlands
Rivium Westlaan 142 Capelle aan den Ijssel 2909 LD
Upjohn EESV
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Neuropathic pain - Pregabalin Pfizer is indicated for the treatment of peripheral and central neuropathic pain in adults. Epilepsy - Pregabalin Pfizer is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised Anxiety Disorder - Pregabalin Pfizer is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Pregabalin Pfizer. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pregabalin Pfizer. For practical information about using Pregabalin Pfizer, patients should read the package leaflet or contact their doctor or pharmacist.